Orthofix Medical (NASDAQ: OFIX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Orthofix Medical reported 29 open-market sales of 657,520 shares ($6.6m) and 16 open-market purchases of 332,754 shares ($4.1m), by 13 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 2 November 2026 | Fisher Patrick | President, Global Limb Recon | Open-market sale, 10b5-1 plan | −150 | $9.07 | 50,769 | Form 4 |
| 1 October 2026 | Fisher Patrick | President, Global Limb Recon | Open-market sale, 10b5-1 plan | −150 | $9.44 | 50,919 | Form 4 |
| 21 September 2026 | Juniper Investment Company, LLC | — | Open-market sale | +190,000 | $8.86 | 3,771,216 | Form 4 |
| 18 September 2026 | Juniper Investment Company, LLC | — | Open-market sale | +120,000 | $8.74 | 3,581,216 | Form 4 |
| 1 September 2026 | Fisher Patrick | President, Global Limb Recon | Open-market sale | −150 | $9.39 | 51,069 | Form 4 |
| 18 August 2026 | Fisher Patrick | President, Global Limb Recon | Open-market sale | −1,295 | $10.09 | 51,219 | Form 4 |
| 17 August 2026 | Michas Alexis P | — | Open-market sale | +20,000 | $10.01 | 84,926 | Form 4 |
| 14 August 2026 | Michas Alexis P | — | Open-market sale | +19,500 | $10.38 | 64,926 | Form 4 |
| 18 June 2026 | McPherron Aviva | Pres, Global Ops & Qual | Open-market sale | −3,670 | $9.38 | 66,330 | Form 4 |
| 10 June 2026 | Paolucci Michael E | Director | Grant or award | +14,965 | — | 102,727 | Form 4 |
| 10 June 2026 | Maniar Shweta | Director | Grant or award | +14,965 | — | 69,038 | Form 4 |
| 10 June 2026 | Burris Wayne | Director | Grant or award | +14,965 | — | 65,504 | Form 4 |
| 10 June 2026 | Henneman John B Iii | Director | Grant or award | +14,965 | — | 105,774 | Form 4 |
| 10 June 2026 | Capps Vickie L | Director | Grant or award | +14,965 | — | 43,300 | Form 4 |
| 10 June 2026 | Finegan Michael | Director | Grant or award | +20,721 | — | 81,617 | Form 4 |
| 10 June 2026 | Hannon Jason | Director | Grant or award | +14,965 | — | 87,662 | Form 4 |
| 10 June 2026 | Kummeth Charles R. | Director | Grant or award | +14,965 | — | 76,305 | Form 4 |
| 10 June 2026 | Bazaar Alan Lee | Director | Grant or award | +14,965 | — | 65,489 | Form 4 |
| 22 May 2026 | Juniper Investment Company, LLC | — | Open-market sale | +242,000 | $10.70 | 3,461,216 | Form 4 |
| 7 May 2026 | Henneman John B Iii | Director | Open-market purchase | +5,000 | $12.26 | 90,809 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Orthofix Medical page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.